Literature DB >> 33468466

In Vitro Resistance and Evolution of Resistance to Tavaborole in Trichophyton rubrum.

Diletta Mazzantini1, Francesco Celandroni1, Marco Calvigioni1, Antonella Lupetti1, Emilia Ghelardi2,3.   

Abstract

Tavaborole is currently used in the topical treatment of onychomycosis. In this study, we analyzed the in vitro emergence/evolution of resistance against tavaborole in Trichophyton rubrum When T. rubrum strains were propagated on media containing the MIC of tavaborole, spontaneous resistant mutants were isolated at a frequency of 10-8 The frequency was almost 100-fold higher following fungal growth in the presence of a subinhibitory tavaborole concentration (0.5-fold the MIC) for 10 transfers. All collected mutants showed similar 4- to 8-fold increases in the drug MIC. No cross-resistance to other antifungals was evident.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  Trichophyton rubrum; cross-resistance; onychomycosis; resistance; tavaborole

Year:  2021        PMID： 33468466      PMCID： PMC8097476          DOI： 10.1128/AAC.02324-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Antifungal resistance mechanisms in dermatophytes.

Authors:  Nilce M Martinez-Rossi; Nalu T A Peres; Antonio Rossi
Journal:  Mycopathologia       Date:  2008-05-14       Impact factor: 2.574

2.  Exploiting evolutionary trade-offs for posttreatment management of drug-resistant populations.

Authors:  Sergey V Melnikov; David L Stevens; Xian Fu; Hui Si Kwok; Jin-Tao Zhang; Yue Shen; Jeffery Sabina; Kevin Lee; Harry Lee; Dieter Söll
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-13       Impact factor: 11.205

3.  A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus.

Authors:  Arya Gupta; Carmine Monteferrante; Dace Rasina; Gundars Leitis; Christopher P Randall; Jennifer H Tomlinson; Aigars Jirgensons; Wil H F Goessens; John P Hays; Alex J O'Neill
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Characterization of benzoxaborole-based antifungal resistance mutations demonstrates that editing depends on electrostatic stabilization of the leucyl-tRNA synthetase editing cap.

Authors:  Jaya Sarkar; Weimin Mao; Tommie L Lincecum; M R K Alley; Susan A Martinis
Journal:  FEBS Lett       Date:  2011-08-16       Impact factor: 4.124

5.  Increase in resistance to fluconazole and itraconazole in Trichophyton rubrum clinical isolates by sequential passages in vitro under drug pressure.

Authors:  Anita Hryncewicz-Gwóźdź; Katarzyna Kalinowska; Ewa Plomer-Niezgoda; Jacek Bielecki; Tomasz Jagielski
Journal:  Mycopathologia       Date:  2013-04-18       Impact factor: 2.574

6.  In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.

Authors:  Xiaoying Hui; Stephen J Baker; Ronald C Wester; Sherry Barbadillo; Anne K Cashmore; Virginia Sanders; Karin M Hold; Tsutomu Akama; Yong-Kang Zhang; Jacob J Plattner; Howard I Maibach
Journal:  J Pharm Sci       Date:  2007-10       Impact factor: 3.534

7.  Recurrent terbinafine resistant Trichophyton rubrum infection in a child with congenital ichthyosis.

Authors:  Louise Schøsler; Louise Kronborg Andersen; Maiken Cavling Arendrup; Mette Sommerlund
Journal:  Pediatr Dermatol       Date:  2018-01-16       Impact factor: 1.588

Review 8.  Onychomycosis: a review.

Authors:  A K Gupta; N Stec; R C Summerbell; N H Shear; V Piguet; A Tosti; B M Piraccini
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-05       Impact factor: 6.166

9.  Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.

Authors:  Daniela Monti; Diletta Mazzantini; Silvia Tampucci; Alessandra Vecchione; Francesco Celandroni; Susi Burgalassi; Emilia Ghelardi
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 10.  Spotlight on tavaborole for the treatment of onychomycosis.

Authors:  Sphoorthi Jinna; Justin Finch
Journal:  Drug Des Devel Ther       Date:  2015-11-20       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.